GLP-1 agonists may be protective against hip fracture when administered for the treatment of type 2 diabetes, according to ...
Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.
The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...
Las inyecciones 'milagro' contra la obesidad sólo sirven si desarrollamos hábitos de vida saludable mientras las estamos ...
The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
4d
Esta alternativa natural del Ozempic actúa solo sobre el cerebro, de manera que produce muchos menos efectos secundarios.
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
El sitio de noticias en español más leído en el mundo. Con redacciones en Ciudad de México, Madrid, Bogotá, Lima y Buenos ...
Expanding coverage and access to glucagon-like peptide-1 (GLP-1) medication can be beneficial for all with the cooperation of multiple parties in health care.
Con más de 200 patologías asociadas, incluyendo enfermedades cardiovasculares, diabetes tipo 2 y distintos tipos de cáncer, ...
Descubre cómo la innovación farmacéutica está transformando el tratamiento de la obesidad y el papel clave del farmacéutico ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback